JOHNSON & JOHNSON (JNJ.DE) Stock Price, Quote, News and Overview
FRA:JNJ - Deutsche Boerse Ag - US4781601046 - Common Stock - Currency: EUR
JNJ.DE Quote, Performance and Key Statistics
JOHNSON & JOHNSON
FRA:JNJ (2/4/2025, 7:00:00 PM)
147.5
+0.38 (+0.26%)
The current stock price of JNJ.DE is 147.5 EUR. In the past month the price increased by 4.85%. In the past year, price increased by 1.65%.
JNJ.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 81.81 | 764.20B | ||
| 1LLY.MI | ELI LILLY & CO | 79.43 | 741.99B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.22 | 413.69B | ||
| NOV.DE | NOVO NORDISK A/S-B | 28.98 | 365.47B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 15.23 | 354.69B | ||
| 1SAN.MI | SANOFI | 14.78 | 260.95B | ||
| SAN.PA | SANOFI | 14.61 | 257.91B | ||
| SNW.DE | SANOFI | 14.58 | 257.34B | ||
| 1MRKX.MI | MERCK & CO. INC. | 16.39 | 238.80B | ||
| 6MK.DE | MERCK & CO. INC. | 15.1 | 220.08B | ||
| 1PFE.MI | PFIZER INC | 10.24 | 145.02B | ||
| PFE.DE | PFIZER INC | 10 | 141.65B |
Related stock screener links
About JNJ.DE
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 131,900 full-time employees. The firm's primary focus is products related to human health and well-being. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 131900
Company Website: https://www.jnj.com/
Investor Relations: https://www.investor.jnj.com
Phone: 17325242455
JNJ.DE FAQ
What is the stock price of JNJ.DE?
The current stock price of JNJ.DE is 147.5 EUR.
What is the symbol for JOHNSON & JOHNSON stock?
The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is JNJ.DE stock listed?
JNJ.DE stock is listed on the Deutsche Boerse Ag exchange.
Is JNJ.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for JNJ.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of JNJ.DE.
Does JNJ.DE stock pay dividends?
JNJ.DE has a dividend yield of 3.24%. The yearly dividend amount is currently 4.46.
What is the Price/Earnings (PE) ratio of JNJ.DE?
The PE ratio for JNJ.DE is 15.25. This is based on the reported non-GAAP earnings per share of 9.67 and the current share price of 147.5 EUR.
JNJ.DE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to JNJ.DE. When comparing the yearly performance of all stocks, JNJ.DE is a bad performer in the overall market: 70.67% of all stocks are doing better.
JNJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE. Both the profitability and the financial health of JNJ.DE get a neutral evaluation. Nothing too spectacular is happening here.
JNJ.DE Financial Highlights
Over the last trailing twelve months JNJ.DE reported a non-GAAP Earnings per Share(EPS) of 9.67. The EPS increased by -4.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.74% | ||
| ROA | 8.24% | ||
| ROE | 20.93% | ||
| Debt/Equity | 0.47 |
JNJ.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to JNJ.DE. The Buy consensus is the average rating of analysts ratings from 30 analysts.
For the next year, analysts expect an EPS growth of 6.61% and a revenue growth 2.48% for JNJ.DE